Trial Profile
A Phase I/II, Open-label, Dose Escalating With 48 Week Treatment Study to Assess the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of BMN053 (Previously Known as PRO053) in Subjects With Duchenne Muscular Dystrophy.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs PRO 053 (Primary) ; PRO 053 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors BioMarin Nederland; BioMarin Pharmaceutical
- 31 May 2016 According to a BioMarin media release, the company intends to discontinue clinical and regulatory development of Kyndrisa as well as the three other first-generation follow-on products, BMN 044, BMN 045 and BMN 053, currently in Phase 2 studies for distinct forms of Duchenne muscular dystrophy.
- 31 May 2016 Status changed from active, no longer recruiting to discontinued, according to a BioMarin media release.
- 06 Jun 2015 Planned number of patients changed from 42 to 45 as reported by ClinicalTrials.gov record.